Table 3 Baseline characteristics and outcomes according to functional outcomes at 3 months of cancer-related stroke
Characteristics | Favorable outcome | Unfavorable outcome | p value |
|---|---|---|---|
3-Month mRS score 0–2 | 3-Month mRS score 3–6 | ||
Total | N = 11 | N = 23 |  |
Age, year, median (IQR) | 70 (57–73.50) | 65 (59–72.50) | 0.690 |
Male | 9 (81.8%) | 8 (34.7%) | 0.026 |
Pre mRS score, median (IQR) | 0 (0–0) | 0 (0–2.5) | 0.153 |
Initial NIHSS score, median (IQR) | 9 (7.5–13.5) | 20 (17–25) | < 0.001 |
Vascular risk factors | |||
 Prior stroke or TIA | 4 (36.3%) | 2 (8.7%) | 0.070 |
 Coronary artery disease | 1 (9.1%) | 4 (17.4%) | 0.507 |
 Hypertension | 7 (63.6%) | 15 (65.2%) | 0.928 |
 Diabetes mellitus | 4 (36.4%) | 8 (34.8%) | 0.928 |
 Dyslipidemia | 4 (36.4%) | 9 (39.1%) | 0.878 |
 Smoking | 3 (27.3%) | 2 (8.7%) | 0.300 |
Previous use of antithrombotics†| 4 (30.8%) | 9 (39.1%) | 0.876 |
Administration of IV-rtPA | 1 (9.1%) | 8 (34.8%) | 0.214 |
Occlusion site | Â | Â | 0.861 |
 Middle cerebral artery, M1 | 5 (45.4%) | 13 (56.5%) |  |
 Middle cerebral artery, M2 | 2 (18.2%) | 4 (17.4%) |  |
 Internal carotid artery | 3 (27.3%) | 2 (8.7%) |  |
 Anterior cerebral artery | 0 (0%) | 1 (4.3%) |  |
 Posterior cerebral artery/Basilar artery | 1 (9.1%) | 3 (13.1%) |  |
In-Hospital Stroke | 4 (36.4%) | 7 (30.4%) | 0.731 |
Time variables | |||
 Onset-to-puncture time, min, SD | 471 (290.24) | 364.39 (224.31) | 0.612 |
 Puncture-to-reperfusion time, min, SD | 74.45 (27.48) | 80.17 (46.13) | 0.856 |
Radiologic Outcomes | |||
 Recanalization status |  |  | 0.160 |
  mTICI 3, 2b | 11 (100%) | 16 (69.6%) |  |
  mTICI 2a | 0 (0%) | 5 (21.7%) |  |
  mTICI 1, 0 | 0 (0%) | 2 (8.7%) |  |
Any cerebral hemorrhage | 1 (9.1%) | 13 (56.5%) | < 0.001 |
 Cancer by location |  |  | 0.510 |
  Pancreatic cancer | 2 (18.2%) | 7 (30.4%) |  |
  Lung cancer | 4 (36.4%) | 3 (13.0%) |  |
  Bile duct cancer | 2 (18.2%) | 3 (13.0%) |  |
  Liver cancer | 1 (9.1%) | 2 (8.7%) |  |
  Gastric cancer | 0 (0%) | 2 (8.7%) |  |
  Colon cancer | 1 (9.1%) | 2 (8.7%) |  |
  Ovarian cancer | 1 (9.1%) | 2 (8.7%) |  |
  Breast cancer | 0 (0%) | 2 (8.7%) |  |
 Cancer stage |  |  | 0.018 |
  III | 7 (63.6%) | 5 (21.7%) |  |
  IV | 4 (36.4%) | 18 (78.3%) |  |
 Cancer type |  |  | 0.280 |
  Adenocarcinoma | 11(100%) | 19 (82.6%) |  |
  Others | 0 (0%) | 4(17.4%) |  |
Systemic metastasis | 4 (36.4%) | 18 (78.3%) | 0.016 |
D-dimer, median (IQR) | 10.7 (6.66–17.71) | 16.95 (14.55–26.60) | 0.028 |